




شبكة المعلومات الجامعية





شبكة المعلومات الجامعية التوثيق الالكتروني والميكروفيلم



شبكة المعلومات الجامعية

جامعة عين شمس

التوثيق الالكتروني والميكرو فيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأفلام قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأفلام بعيدا عن الغبار

في درجة حرارة من ١٥-٢٥ مئوية ورطوبة نسبية من ٢٠-٤٠%

To be Kept away from Dust in Dry Cool place of
15-25- c and relative humidity 20-40 %

بالرسالة صفحات لـ



شبكة المعلومات الجامعية
@ ASUNET

بعض الوشائج
شبكة المعلومات
Ain Shams University
Information Network
جامعة عين شمس

شبكة المعلومات الجامعية
@ ASUNET

Zagazig University
Banha Faculty of Medicine
Department of Internal Medicine

SIROLIMUS BASED THERAPY IN LIVE DONOR RENAL TRANSPLANTATION-A PROSPECTIVE RANDOMIZED STUDY

A THESIS

Submitted In Partial Fulfillment of the M.D. IN Internal Medicine

By

AHMED FAROUK HAMDY

**M.Sc. Internal Medicine
Urology and Nephrology Center,
Faculty of Medicine, Mansoura University**

SUPERVISORS

Prof. Dr.

El-Metwally El-Shahawy

**Prof. and Head of Internal
Medicine Department & Nephrology unit
Banha Faculty of Medicine
Zagazig University**

Prof. Dr.

MOHAMED A. GHONEIM

**Prof. of Urology
Urology & Nephrology Center
Faculty of Medicine
Mansoura University**

Prof. Dr.

Sameh Bahgat

**Prof. of Internal Medicine
Banha Faculty of Medicine
Zagazig University**

Prof. Dr.

Hasan Galal

**Assist. Prof. of Internal Medicine
Banha Faculty of Medicine
Zagazig University**

Dr.

Amgad El-baz El-Agroudy

**Fellow of Internal Medicine
Urology & Nephrology Center
Mansoura University**

2003



27.1

**Zagazig University
Banha Faculty of Medicine
Department of Internal Medicine**

SIROLIMUS BASED THERAPY IN LIVE DONOR RENAL TRANSPLANTATION-A PROSPECTIVE RANDOMIZED STUDY

A THESIS

Submitted In Partial Fulfillment of the M.D. IN Internal Medicine

By

AHMED FAROUK HAMDY

**M.Sc. Internal Medicine
Urology and Nephrology Center,
Faculty of Medicine, Mansoura University**

SUPERVISORS

**Prof. Dr.
El-Metwally El-Shahawy
Prof. and Head of Internal
Medicine Department & Nephrology unit
Banha Faculty of Medicine
Zagazig University**

**Prof. Dr.
MOHAMED A. GHONEIM
Prof. of Urology
Urology & Nephrology Center
Faculty of Medicine
Mansoura University**

**Prof. Dr.
Sameh Bahgat
Prof. of Internal Medicine
Banha Faculty of Medicine
Zagazig University**

**Prof. Dr.
Hasan Galal
Assist. Prof. of Internal Medicine
Banha Faculty of Medicine
Zagazig University**

**Dr.
Amgad El-baz El-Agroudy
Fellow of Internal Medicine
Urology & Nephrology Center
Mansoura University**

2003

Faithfully Dedicated

To

My Wife

&

My Son Omar

ACKNOWLEDGMENT

First and foremost, thanks to Allah.

I wish to express my deep gratitude to **Prof. Dr. Mohamed A. Ghoneim**, Professor of Urology, Urology & Nephrology Center, Mansoura University and the pioneer of renal transplantation for his sincere supervision, valuable criticism and guidance. His valuable support and continuous effort were the driving force behind the accomplishment of this work.

I am especially grateful to **Prof. Dr. El-Metwaily El-Shahawy**, Prof. and Head of Internal Medicine Dept. and Nephrology Unit, Banha Faculty of medicine for his continuous help, generous guidance, constructive criticism and encouragement.

I wish to express my sincere thanks to **Prof. Dr. Sameh Bahgat**, Prof. of Internal Medicine, Banha Faculty of medicine for his kind help and advice.

My deep gratitude must go to **Dr. Hasan Galal** Assist. Prof. of Internal Medicine, Banha Faculty of Medicine for his kind supervision.

I am especially grateful to **Dr. Amgad El-Baz**, fellow of internal medicine, Urology & Nephrology Center, Mansoura University for his valuable advice and kind supervision during conduction of this thesis.

I am deeply indepted to **Dr. Adel Bakr**, Senior Consultant of Nephrology, Urology & Nephrology Center for his unlimited effort, guidance and for giving generously his time.

My deep gratitude to my colleagues in the Nephrology Unit who assisted me during this work as well as all urologists, pathologists, radiologists and laboratory personell who shared in this work.

Valuable secretarial support has been provided by Miss. Eman Abdelfattah and all members of medical secretary who had been skillful and patient in typing this work.

List of Abbreviations

ATG	antithymocyte globulin
ATGAM	Polyclonal antilymphocyte antibody
AUC	area under the concentration time curve
aza	Azathioprine
C min	minimum concentration
CADI	chronic allograft damage index
CAN	Chronic allograft nephropathy
CD	cluster of differentiation
cmax	peak whole blood concentration
CMV	cytomegalo virus
CNAs	calcineurin antagonists
CR	chronic rejection
CsA	Cyclosporine
CYP	cytochrome
DNA	Deoxy nucleic acid
EBV	Epstein-Barr virus
ELISA	Enzyme linked immunosorbent assay
FK BP12	FK binding protein 12
FSGS	Focal segmental glomerulosclerosis
GFR	glomerular filtration rate
GM-CSF	Granulocyte macrophage colony stimulating factor
HCV	hepatitis C virus
HDL	high density lipoprotein
HLA	human leukocyte antigen
HMG-CoA	Hydroxy methyl glutaryl-Coenzyme A
HPLC	high performance liquid chromatography
IBA	Immunophilin binding assay
IFN	interferon

IgG	Immunoglobulin G
IL-2	Interleukin 2
LDL	low density lipoprotein
MEIA	microparticle enzyme immunoassay
MHC	Major histocompatibility complex
MMF	Mycophenolate mofetil
MpA	mycophenolic acid
MPGN	membranoproliferative glomerulonephritis
MRA	Magnetic resonance angiography
MRI	Magnetic resonance imaging
mRNA	messenger ribonucleic acid
MRU	Magnetic resonance urography
MS	Mass spectrometry
NF-KB	nuclear factor kappa B
OKT3	orthoclone monoclonal antibody
PCNA	Proliferating cell nuclear antigen
PPIase	Cis/trans peptidyl prolyl isomerase
PTDM	Post-transplant diabetes mellitus
PTLD	post-transplant lympho proliferative disorder
RBF	renal blood flow
SD	standard deviation
SGOT	serum glutamic oxalacetic transaminase
SGPT	serum glutamic pyruvic transaminase
SRL	Sirolimus
TGB-B	Transforming growth factor B
tmax	mean time to peak whole blood concentration
TNF α	Tumour necrosis factor α
TOR	Target of rapamycin
TRL	Tacrolimus
US	United States

List of Contents

	Page
= Introduction-----	1
= Aim of the work-----	6
= Review of Literature	
• Evolution of immunosuppression :	
- History of immunosuppression-----	7
- Utilization of immunosuppressants-----	9
- Groups of immunosuppression drugs-----	10
• Sirolimus :	
- Introduction-----	24
- Physical, chemical, pharmaceutical properties and formulation	24
- Non-clinical pharmacology-----	25
- Pharmacokinetics-----	31
- Clinical effectiveness-----	37
- Therapeutic monitoring-----	52
- Safety and toxicity-----	55
• Factors affecting graft survival-----	66
= Patients and Methods-----	75
= Results-----	82
= Discussion-----	125
= Summary and Conclusions-----	142
= References-----	144
= Arabic Summary	

List of Tables

	Page
• Table (1) : Demography and base line characteristics	
a) Clinical data-----	93
b) Donor/Recipient data-----	94
c) Surgical aspects-----	95
d) Laboratory profile-----	96
• Table (2) : Immunosuppressive medications	
a) Mean tacrolimus dosage and level in group A-----	97
b) Mean MMF dosage in group B-----	100
c) Mean sirolimus dose in both groups-----	101
d) Mean sirolimus level in both groups-----	103
• Table (3) : Graft function in both groups	
a) Serum creatinine-----	105
b) Calculated GFR -----	105
Comparison of laboratory profile	
c) Hematology-----	107
d) Biochemistry-----	108
e) Liver function tests-----	109
f) Lipid profile-----	110
g) 24 hour urinary protein excretion-----	112
• Table (4) :	
a) Incidence and frequency of acute rejection episodes-----	113
b) Histopathological examination of graft biopsies-----	113
C.I) Chronic allograft damage index of one year protocol biopsies	117

II) Incidence of histological findings in renal allograft protocol biopsies-----	117
---	-----

• **Table (5) : Adverse events**

a- Medical complications

a-I) Changes in the control of hypertension-----	119
a-II) New onset diabetes Mellitus-----	119
a-III) Hyperlipidemia-----	119
a-IV) Hematologic complications-----	120
a-V) Infections-----	120
a-VI) Proteinuria-----	121
a-VII) High liver Enzymes-----	121
a-VIII) Bone disease-----	121
a-IX) Miscellaneous-----	122

b- Surgical complications----- 122

• **Table (6) : Patient and graft outcome at the end of the study-----** 123

List of Diagrams

Diagram (A): Immunosuppression protocol-----	Page 81
Diagram (B): Mean tacrolimus dose at different follow up periods in group A patients-----	98
Diagram (C): mean tacrolimus level at different follow up periods in group A patients-----	99
Diagram (D): Mean sirolimus dose in both groups at different follow up periods-----	102
Diagram (E): Mean siroloimus level in both groups at different follow up periods-----	104
Diagram (F): Graft function in both groups at different follow up Periods-----	106
Diagram (G): Incidence and frequency of acute rejection episodes----	114
Diagram (H): graft survival relative to primary immunosuppression--	124